Evidence map›Paper›PMID 38843233›Full record

ArticlePloS one2024

Malic enzyme 1 knockout has no deleterious phenotype and is favored in the male germline under standard laboratory conditions.

Jonathan M Alektiar, Mengrou Shan, Megan D Radyk, Li Zhang, Christopher J Halbrook, Lin Lin, Carlos Espinoza, Ivan F Mier, Brooke L Lavoie, Lucie Salvatore and 4 more

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jonathan M AlektiarDepartment of Molecular & Integrative Physiology, University of Michigan, Ann Arbor, Michigan, United States of America.ORCID 0000-0002-3343-0993
Mengrou ShanDepartment of Molecular & Integrative Physiology, University of Michigan, Ann Arbor, Michigan, United States of America.
Megan D RadykDepartment of Molecular & Integrative Physiology, University of Michigan, Ann Arbor, Michigan, United States of America.
Li ZhangDepartment of Molecular & Integrative Physiology, University of Michigan, Ann Arbor, Michigan, United States of America.
Christopher J HalbrookDepartment of Molecular & Integrative Physiology, University of Michigan, Ann Arbor, Michigan, United States of America.ORCID 0000-0002-3376-3114
Lin LinDepartment of Molecular & Integrative Physiology, University of Michigan, Ann Arbor, Michigan, United States of America.
Carlos EspinozaDepartment of Surgery, University of Michigan, Ann Arbor, Michigan, United States of America.
Ivan F MierDepartment of Human Genetics, University of Michigan, Ann Arbor, Michigan, United States of America.
Brooke L LavoieDepartment of Molecular & Integrative Physiology, University of Michigan, Ann Arbor, Michigan, United States of America.
Lucie SalvatoreDepartment of Molecular & Integrative Physiology, University of Michigan, Ann Arbor, Michigan, United States of America.
Marina Pasca di MaglianoDepartment of Surgery, University of Michigan, Ann Arbor, Michigan, United States of America.
Lewis C CantleyDepartment of Cancer Biology, Dana Farber Cancer Center, Boston, Massachusetts, United States of America.
Jacob L MuellerDepartment of Human Genetics, University of Michigan, Ann Arbor, Michigan, United States of America.
Costas A LyssiotisDepartment of Molecular & Integrative Physiology, University of Michigan, Ann Arbor, Michigan, United States of America.ORCID 0000-0001-9309-6141

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Alexey I Nesvizhskii · 1988 to 2026
$178.2M
Role of Phosphoinositides and Protein Kinases in the control of Cancer MetabolismR35CA197588 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LEWIS C. CANTLEY · 2016 to 2026
$10.2M
Structure, Composition, & Histology Core - Core BP30AR069620 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KARL J JEPSEN · 2016 to 2026
$8.4M
TRAINING PROGRAM IN ORGANOGENESIST32HD007505 · NICHD · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PASCA DI MAGLIANO, MARINA, SPENCE, JASON · 1997 to 2021
$6.9M
Defining and Targeting Malic Enzyme Dependence in Pancreatic CancerF32CA247492 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SHAN, MENGROU · 2020 to 2023
$204k
Metabolic pathways regulate metaplasia and cancer initiation in the pancreasF32CA275283 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI RADYK, MEGAN DEANNA · 2023 to 2023
$70k
NCI NIH HHS F32 CA247492NCI NIH HHS F32 CA275283NCI NIH HHS P30 CA046592NCI NIH HHS R35 CA197588NIAMS NIH HHS P30 AR069620NICHD NIH HHS T32 HD007505
6 · The paper itself

Abstract

Malic Enzyme 1 (ME1) plays an integral role in fatty acid synthesis and cellular energetics through its production of NADPH and pyruvate. As such, it has been identified as a gene of interest in obesity, type 2 diabetes, and an array of epithelial cancers, with most work being performed in vitro. The current standard model for ME1 loss in vivo is the spontaneous Mod-1 null allele, which produces a canonically inactive form of ME1. Herein, we describe two new genetically engineered mouse models exhibiting ME1 loss at dynamic timepoints. Using murine embryonic stem cells and Flp/FRT and Cre/loxP class switch recombination, we established a germline Me1 knockout model (Me1 KO) and an inducible conditional knockout model (Me1 cKO), activated upon tamoxifen treatment in adulthood. Collectively, neither the Me1 KO nor Me1 cKO models exhibited deleterious phenotype under standard laboratory conditions. Knockout of ME1 was validated by immunohistochemistry and genotype confirmed by PCR. Transmission patterns favor Me1 loss in Me1 KO mice when maternally transmitted to male progeny. Hematological examination of these models through complete blood count and serum chemistry panels revealed no discrepancy with their wild-type counterparts. Orthotopic pancreatic tumors in Me1 cKO mice grow similarly to Me1 expressing mice. Similarly, no behavioral phenotype was observed in Me1 cKO mice when aged for 52 weeks. Histological analysis of several tissues revealed no pathological phenotype. These models provide a more modern approach to ME1 knockout in vivo while opening the door for further study into the role of ME1 loss under more biologically relevant, stressful conditions.

Indexed as

Malate DehydrogenaseMice, KnockoutPhenotypeAnimalsFemaleGerm CellsMaleMiceMice, Inbred C57BLMalate Dehydrogenasemalate dehydrogenase (decarboxylating)

Identifiers

PMID38843233
PMCPMC11156412

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.